ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals Stock Forecast

Stock Price Forecast

The 4 analysts that cover ARS Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $31.25, which forecasts a 168.47% increase in the stock price over the next year. The lowest target is $27 and the highest is $40.

Price Target: $31.25 (+168.47%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$27	$31.25	$30	$40
Change	+131.96%	+168.47%	+157.73%	+243.64%

* Price targets were last updated on Sep 4, 2025.

Analyst Ratings

The average analyst rating for ARS Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	1	1	2	2	2	2
Buy	4	4	3	3	3	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason Wittes Roth Capital	Roth Capital	Strong Buy Initiates $40	Strong Buy	Initiates	$40	+243.64%	Sep 4, 2025
Louise Chen Scotiabank	Scotiabank	Buy Initiates $30	Buy	Initiates	$30	+157.73%	Mar 7, 2025
Ryan Deschner Raymond James	Raymond James	Strong Buy Maintains $26 → $28	Strong Buy	Maintains	$26 → $28	+140.55%	Jan 14, 2025
Roanna Ruiz Leerink Partners	Leerink Partners	Buy Maintains $26 → $27	Buy	Maintains	$26 → $27	+131.96%	Jan 13, 2025
Josh Schimmer Cantor Fitzgerald	Cantor Fitzgerald	Buy Reiterates $30	Buy	Reiterates	$30	+157.73%	Oct 8, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

82.88M

Decreased by -7.04%

from 89.15M

Revenue Next Year

188.80M

Increased by 127.81%

from 82.88M

EPS This Year

-1.76

from 0.08

EPS Next Year

-1.33

from -1.76

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	17.84M	5.51M	1.32M	30.00K	89.15M	82.88M	188.80M
Revenue Growth	-	-69.13%	-76.10%	-97.72%	297,063.33%	-7.04%	127.81%
EPS	-0.05	-0.70	-0.87	-0.57	0.08	-1.76	-1.33
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	8	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	89.4M	247.8M
Avg	82.9M	188.8M
Low	76.4M	148.0M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	0.3%	199.0%
Avg	-7.0%	127.8%
Low	-14.3%	78.6%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	-1.46	-0.97
Avg	-1.76	-1.33
Low	-1.85	-2.08

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.